Oxybutynin/pilocarpine - Dermavant Sciences/Theravida

Drug Profile

Oxybutynin/pilocarpine - Dermavant Sciences/Theravida

Alternative Names: pilocarpine/oxybutynin; RVT 504; THVD-101a; THVD-102

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TheraVida
  • Class Alkaloids; Carbocyclic acids; Furans; Imidazoles; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Hyperhidrosis; Overactive bladder

Most Recent Events

  • 29 Jun 2018 Chemical structure information added
  • 03 Apr 2018 Oxybutynin/pilocarpine licensed to Dermavant Sciences
  • 03 Apr 2018 TheraVida completes a phase IIa trial in Hyperhidrosis in Australia before June 2018 (Roivant Sciences pipeline, June 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top